ORAL DRUG DELIVERY161

Issue No #161 June 17th, 2024

Inside the magazine

NAVIGATING THE TRANSITION: EXPLORING ALTERNATIVES TO TiO<sub>2</sub> IN PHARMACEUTICAL FORMULATIONS

Lucia Gurruchaga

NAVIGATING THE TRANSITION: EXPLORING ALTERNATIVES TO TiO₂ IN PHARMACEUTICAL FORMULATIONS

Lucía Gurruchaga discusses the push to develop an alternative opacifier and white colourant to titanium dioxide in the wake of the European Commission’s announcement that the additive may be banned in medicinal products, presenting data from recent testing on Qualicaps’ own novel alternative.

TARGETING NITROSAMINE PRECURSORS WITH NOVEL ACTIVE MATERIAL SCIENCE SCAVENGER TECHNOLOGIES

Aptar CSP Technologies

TARGETING NITROSAMINE PRECURSORS WITH NOVEL ACTIVE MATERIAL SCIENCE SCAVENGER TECHNOLOGIES

Ivy Comer, Amanda Murph and Jason Pratt, discuss the challenges in combatting N-nitrosamine formation in oral solid dosage forms, and present Aptar’s 3-Phase Activ-Polymer technology as a novel packaging-based solution.

TACKLING IRON-DEFICIENCY ANAEMIA: A LEAP FORWARD WITH A REVOLUTIONARY BUCCAL PATCH

Dr Buddhadev Chaudhuri

TACKLING IRON-DEFICIENCY ANAEMIA: A LEAP FORWARD WITH A REVOLUTIONARY BUCCAL PATCH

Buddhadev P Chaudhuri and Frederik Ceyssens, discuss the challenges of iron-deficiency anaemia and introduce Keylika’s new buccal patch for iron delivery.

ADAPTING TO AN AGEING WORLD: FORMULATION STRATEGIES TO BOOST PATIENT COMPLIANCE

ADAPTING TO AN AGEING WORLD: FORMULATION STRATEGIES TO BOOST PATIENT COMPLIANCE

Jason Hunt and Yeli Zhang discuss the key factors undermining patient compliance in older adults and explore how the pharmaceutical industry can leverage excipients to enhance drug formulations and improve medication compliance among this critical demographic.

ARE ORAL FORMULATIONS OF OLIGONUCLEOTIDE THERAPEUTICS WITHIN REACH?

ARE ORAL FORMULATIONS OF OLIGONUCLEOTIDE THERAPEUTICS WITHIN REACH?

Nigel Theobald, discusses key issues and strategies for formulation scientists aiming to unlock the potential of oral delivery for small interfering ribonucleic acid drugs targeted against gastrointestinal diseases and cancers.

DIFFERENTIATING ORAL SUSPENSIONS WITH VERSATILE EXCIPIENTS

Mariona Venceslao Molins

DIFFERENTIATING ORAL SUSPENSIONS WITH VERSATILE EXCIPIENTS

Mariona Venceslao Molins and Liliana Miinea discuss how excipient-based approaches can facilitate patient-centric formulations and transform oral suspensions.

STRATEGIES TO MITIGATE GELATIN CROSS-LINKING IN ORAL SOLID DRUG DELIVERY

Dr Jnanadeva Bhat

STRATEGIES TO MITIGATE GELATIN CROSS-LINKING IN ORAL SOLID DRUG DELIVERY

Jnanadeva Bhat and Manali Dalvi discuss the factors contributing to gelatin cross-linking in oral solid dose delivery – and strategies to tackle the resulting challenges.

CANNABIDIOL DELIVERY THAT IS ON THE “TIP OF THE TONGUE”

Dr Zdravka Misic

CANNABIDIOL DELIVERY THAT IS ON THE “TIP OF THE TONGUE”

Zdravka Misic explores how formulation expertise can be applied to overcome the low bioavailability of cannabinoids and how innovation in orally disintegrating tablets is driving progress for cannabidiol-based therapeutics.

Top